LEADER 05245nam 2200601 a 450 001 9910841216203321 005 20230721030251.0 010 $a1-281-03198-4 010 $a9786611031985 010 $a0-470-51309-8 010 $a0-470-51308-X 035 $a(CKB)1000000000377301 035 $a(EBL)316236 035 $a(OCoLC)476106855 035 $a(SSID)ssj0000123520 035 $a(PQKBManifestationID)11143360 035 $a(PQKBTitleCode)TC0000123520 035 $a(PQKBWorkID)10014335 035 $a(PQKB)10019298 035 $a(MiAaPQ)EBC316236 035 $a(EXLCZ)991000000000377301 100 $a20070416d2007 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aClinical diabetes research$b[electronic resource] $emethods and techniques /$fedited by Michael Roden 210 $aChichester, West Sussex, England ;$aHoboken, N.J. $cJohn Wiley and Sons$dc2007 215 $a1 online resource (424 p.) 300 $aDescription based upon print version of record. 311 $a0-470-01728-7 320 $aIncludes bibliographical references and index. 327 $aClinical Diabetes Research; Contents; List of Contributors; 1 Basics of Clinical Metabolic Research; 2 Methods for the Assessment of ?-Cell Function In Vivo; Introduction; Methods for insulin secretion in vivo; ?-cell response characteristics; ?-cell function tests; Modelling methods; ?-cell function and insulin sensitivity; Comparative evaluation of methods; Conclusion; 3 Assessment of Insulin Sensitivity from Steady-State and Dynamic Tests; Introduction; Insulin sensitivity from steady-state tests; Insulin sensitivity from dynamic tests; Conclusion; 4 Glucose Clamp Techniques; Introduction 327 $aBasic principles of the euglycaemic hyperinsulinaemic clamp techniqueMethodology; Reproducibility of insulin sensitivity obtained from clamp tests; Safety considerations for hyperinsulinaemiac euglycaemic clamp test; Modifications of the euglycaemic hyperinsulinaemic clamp test protocol; Conclusion; 5 Methods of Assessment of Counterregulation to Hypoglycaemia; Introduction; Definitions; Pathophysiology; Documentation of hypoglycaemia experience; Investigating the pathogenesis of problematic hypoglycaemia; Hypoglycaemic stimuli for research; Measurement of physiological responses; Conclusion 327 $a6 Glucose Kinetics: Measurement of Flux RatesIntroduction; Measurement of glucose production and uptake by the liver - tissue balance techniques; Properties of glucose tracers; Measurement of glucose production and uptake by the liver - systemic techniques; Conclusion; Acknowledgements; 7 Xenobiotics as Probes of Carbohydrate Metabolism; Introduction; Glucuronidation; Glutamination; Ribosylation; Acetylation; Glycination; 8 Tracing Hepatic Glucose and Glycogen Fluxes with 2H2O; Introduction; Methodology; Theoretical considerations; Quantifying hepatic glucose and glycogen metabolism 327 $aConclusion9 Lipid Kinetics; Introduction; Tracers for the study of adipose tissue lipolysis; Tracers for the study of triglyceride-rich lipoprotein kinetics; Conclusion; Acknowledgements; 10 Protein and Amino Acid Kinetics; Introduction; Measuring amino acid turnover; Measuring protein turnover; Proteome dynamics; Urea kinetics; Determining the molecular control of protein dynamics; Conclusion; Acknowledgements; 11 Assessment of Metabolic Fluxes by In Vivo MR Spectroscopy; Phenomena of nuclear magnetic resonance - imaging and spectroscopy; Skeletal muscle; Liver; Brain; Conclusion 327 $a12 Positron Emission Tomography in Metabolic ResearchIntroduction; Tracers for metabolic imaging; Principles of modeling; Future perspectives; 13 Assessment of Body Fat Content and Distribution; Introduction; Measurement techniques; Body fat distribution and insulin resistance; 14 Tissue Biopsies in Diabetes Research; Introduction; Percutaneous needle biopsy of skeletal muscle; Biopsy procedure and sample handling; Discomfort and complications of needle biopsy; Advantages and limitations of needle biopsy; Application of muscle biopsy in diabetes; Morphology of skeletal muscle 327 $aApplication of muscle morphology in type 2 diabetes 330 $aA practical ""how to"" guide for multiple methods in metabolism, with a critical and objective discussion of strengths, limitations, and appropriate applications of the described methods. Edited by the winner of the Oskar-Minkowski Prize of the EASD in 2006 Clinical trials in populations at risk of or with overt diabetes mellitus are being performed all around the world to test novel drugs and approaches to managing these diseases. During the last decade, new methods and techniques have been introduced - and are being developed further - that facilitate monitoring of metaboli 606 $aDiabetes 606 $aDiabetes$xResearch 615 0$aDiabetes. 615 0$aDiabetes$xResearch. 676 $a616.4620072 701 $aRoden$b Michael$cDr.$01730348 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910841216203321 996 $aClinical diabetes research$94141396 997 $aUNINA